Amniotic fluid-derived stem cells as an effective cell source for transplantation therapy in stroke

This review examines stem cells harvested from human amniotic fluid and considers their possible applications in regenerative medicine, specifically for stroke therapy. Providing an early-stage, highly differentiable source of mesenchymal stem cells, amniotic fluid shows the potential to be effective in the development of future stem cell-based transplantation. This paper underscores the importance of pursuing amniotic fluid as a stem cell source in stroke therapy, citing both the characteristics and the demonstrated functional benefits of these cells in animal models. Additional research is required to discover the full range of amniotic fluid-derived stem cells′ (AFSCs) applications but these cells have thus far demonstrated the ability to be applied to a wide array of existing and future treatment methods. Both amniotic fluid- and amnion membrane-derived stem cells (AMSCs) have their merits, and this assessment will accordingly provide a comparison of the benefits and drawbacks of both cell sources